JP7442624B2 - 肢虚血を治療するための活性化間葉系幹細胞 - Google Patents
肢虚血を治療するための活性化間葉系幹細胞 Download PDFInfo
- Publication number
- JP7442624B2 JP7442624B2 JP2022512807A JP2022512807A JP7442624B2 JP 7442624 B2 JP7442624 B2 JP 7442624B2 JP 2022512807 A JP2022512807 A JP 2022512807A JP 2022512807 A JP2022512807 A JP 2022512807A JP 7442624 B2 JP7442624 B2 JP 7442624B2
- Authority
- JP
- Japan
- Prior art keywords
- mscs
- treated
- metamizole
- admscs
- stem cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims description 58
- 201000002818 limb ischemia Diseases 0.000 title claims description 6
- 238000011282 treatment Methods 0.000 claims description 50
- 210000004027 cell Anatomy 0.000 claims description 37
- 229940120889 dipyrone Drugs 0.000 claims description 31
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 14
- 210000000577 adipose tissue Anatomy 0.000 claims description 10
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims description 7
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 7
- 230000001172 regenerating effect Effects 0.000 claims description 7
- 230000028327 secretion Effects 0.000 claims description 7
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 claims description 6
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 claims description 6
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims description 6
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims description 6
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 claims description 6
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims description 5
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims description 5
- 230000002491 angiogenic effect Effects 0.000 claims description 5
- 230000000770 proinflammatory effect Effects 0.000 claims description 5
- 230000037396 body weight Effects 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000014509 gene expression Effects 0.000 description 45
- 241001465754 Metazoa Species 0.000 description 41
- 230000033115 angiogenesis Effects 0.000 description 22
- 230000000694 effects Effects 0.000 description 22
- 239000002158 endotoxin Substances 0.000 description 21
- 229920006008 lipopolysaccharide Polymers 0.000 description 21
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 19
- 230000002757 inflammatory effect Effects 0.000 description 18
- 108090000695 Cytokines Proteins 0.000 description 17
- 238000001356 surgical procedure Methods 0.000 description 17
- 239000003814 drug Substances 0.000 description 16
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 15
- 102000004127 Cytokines Human genes 0.000 description 15
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 15
- 230000027746 artery morphogenesis Effects 0.000 description 15
- 229960005489 paracetamol Drugs 0.000 description 15
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 14
- 108090001005 Interleukin-6 Proteins 0.000 description 14
- 102000004889 Interleukin-6 Human genes 0.000 description 14
- 230000010412 perfusion Effects 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 230000002503 metabolic effect Effects 0.000 description 13
- 108020004999 messenger RNA Proteins 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 11
- 229960005205 prednisolone Drugs 0.000 description 11
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 10
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 10
- 102100026236 Interleukin-8 Human genes 0.000 description 10
- 229940124599 anti-inflammatory drug Drugs 0.000 description 10
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 10
- 229960000991 ketoprofen Drugs 0.000 description 10
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 9
- 229960001259 diclofenac Drugs 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 description 8
- 206010034576 Peripheral ischaemia Diseases 0.000 description 8
- 239000002870 angiogenesis inducing agent Substances 0.000 description 6
- 230000022131 cell cycle Effects 0.000 description 6
- 230000002519 immonomodulatory effect Effects 0.000 description 6
- 230000000302 ischemic effect Effects 0.000 description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 5
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 5
- 102100026019 Interleukin-6 Human genes 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 238000002583 angiography Methods 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 210000003414 extremity Anatomy 0.000 description 5
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 5
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 208000028867 ischemia Diseases 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000008081 blood perfusion Effects 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 238000010219 correlation analysis Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000002695 general anesthesia Methods 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 230000035519 G0 Phase Effects 0.000 description 2
- 230000010190 G1 phase Effects 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 2
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 2
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 108091058560 IL8 Proteins 0.000 description 2
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 2
- 102100039065 Interleukin-1 beta Human genes 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001772 anti-angiogenic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000006369 cell cycle progression Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000003090 iliac artery Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 238000011542 limb amputation Methods 0.000 description 2
- 238000007443 liposuction Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 2
- 229910052715 tantalum Inorganic materials 0.000 description 2
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 2
- 230000001228 trophic effect Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZAUYNCUCMJDAHW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;hydrogen peroxide;molecular iodine Chemical compound OO.II.C=CN1CCCC1=O ZAUYNCUCMJDAHW-UHFFFAOYSA-N 0.000 description 1
- 101710163391 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- -1 CCL3 Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 1
- 101000847156 Homo sapiens Tumor necrosis factor-inducible gene 6 protein Proteins 0.000 description 1
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102000043168 TGF-beta family Human genes 0.000 description 1
- 108091085018 TGF-beta family Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100032807 Tumor necrosis factor-inducible gene 6 protein Human genes 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000001623 arteriogenic effect Effects 0.000 description 1
- HSWPZIDYAHLZDD-UHFFFAOYSA-N atipamezole Chemical compound C1C2=CC=CC=C2CC1(CC)C1=CN=CN1 HSWPZIDYAHLZDD-UHFFFAOYSA-N 0.000 description 1
- 229960003002 atipamezole Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 230000018486 cell cycle phase Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000008975 immunomodulatory function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HRLIOXLXPOHXTA-UHFFFAOYSA-N medetomidine Chemical compound C=1C=CC(C)=C(C)C=1C(C)C1=CN=C[N]1 HRLIOXLXPOHXTA-UHFFFAOYSA-N 0.000 description 1
- 229960002140 medetomidine Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 210000003137 popliteal artery Anatomy 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000006884 regulation of angiogenesis Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000006492 vascular dysfunction Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
脂肪組織を採取することと、
脂肪組織から間葉系幹細胞を分離することと、
MSCを再生することと、
MSCに活性成分を作用させることとを含む。
代謝活性に対するパラセタモール(4.4mM)、ジクロフェナク(10μM)、メタミゾール(analgin)(10μM)、ケトプロフェン(50μM)及びプレドニゾロン(0.1μM)の効果の分析を、ドナー変異の効果を低下させるために少なくとも3人のドナーから単離されたAdMSCのプールを使用して行った。代謝活性アッセイ(WST-1)データは、AIDがAdMSCの代謝活性をわずかに変化させることを示した(図1)。最初の48時間の間、分析した全てのAIDがAdMSCの代謝活性を刺激した。メタミゾール(analgin)処置は最初の24時間で細胞代謝を有意に刺激したが、試験した全ての薬物はAdMSCの代謝活性に対する長期抑制効果を示した(図1)。
MSCによって産生される多数の可溶性因子が、インビボでの血管形成及び血管新生の調節に関与する(Estradaら、2009年)。一方、MSCは、特定の条件において血管形成を阻害することが明らかにされている(Otsuら、2009年)。また、栄養因子VEGF及びbFGFは、虚血の処置において血管形成を刺激することが示されている(Leungら、1989年)。AdMSCにおける血管新生因子の発現に対するAIDの効果を分析した。異なるAIDは、それらの発現を刺激するか又は抑制するかのいずれかで血管新生因子の発現に異なって影響した。メタミゾール(analgin)及びケトプロフェンによるAdMSCの処置は、VEGFA、HGF、bFGF及びTEK mRNA発現の上方制御をもたらし(図3)、ジクロフェナクは効果がなく、パラセタモール及びプレドニゾロンはVEGFA及びHGF発現を阻害した。更に、パラセタモールはbFGFを誘導したが、TEK発現を強く抑制したのに対して、プレドニゾロンは反対の効果を有した(図3)。
MSCによって分泌されるいくつかの炎症性サイトカイン及びケモカインは、免疫調節のプロセスに関与し、それにより、免疫担当細胞に影響を及ぼす。MSCによって分泌されるサイトカインのレベルにおける定量的差異は、微小環境の局所的条件を決定し、抗炎症反応を誘導する。AID処置と組み合わせたMSC治療に応答した炎症性バイオマーカープロファイルの同定は、全体として免疫学的状態に対するそのような介入の結果を予測することができた。タンパク質及び遺伝子発現レベルでのAdMSCの炎症プロファイルに対するAID処置の効果を分析した。
前臨床研究の目的は、別々に単離され、条件的に操作されたヒトAdMSCを比較することによって、血管新生及び動脈新生を最も促進する条件及び細胞を評価することであった。これらのタイプの前臨床研究は、後肢虚血モデル(HLIM)の使用を意味し、虚血性筋肉の血行再建の回復は、投与された薬物(細胞)の再生能に起因して生じるが、動物自身の再生能力によるものではない。この虚血ウィンドウは、少なくとも2~3週間続くべきである。このモデルでは、更に、インビボ再生のためのAdMSCの試験によく適しているHLIMのヘリングマンモデルの開発に成功した。
BEAULI:ボディジェット(軟組織欠損を処置するためのヒト医療の日常的な臨床診療)を使用して得た吸引脂肪組織。吸引脂肪組織は、水ジェット支援脂肪吸引を使用して得られる。採取した脂肪を、LipoCollector(登録商標)又はFillerCollector(登録商標)を用いて残りの流体から穏やかに分離し、脂肪移植のために直ちに使用した。この技術は、脂肪細胞移植の臨床標準として使用されてきた。
前臨床動物試験のために、4つの異なる処置(BEAULI、CYTORI、MSC及びMSCD)を試験した。各シリーズにおいて、11匹の動物を手術し、8匹を腓腹筋に注射した異なる細胞で処置し、3匹の対照動物を生理食塩水で処置した。更に、6匹の動物の別個の対照シリーズを手術した。
動物を全身麻酔(ケタミン(100mg/ml、Vetoquinol社、フランス)とメデトミジン(1mg/ml、Syva社、スペイン)の混合液をそれぞれ75mg/kgと0.5mg/kgを腹腔内に投与)下で仰臥位で手術した。右肢を切開した。外腸骨動脈、大腿動脈、膝窩動脈及び全ての側枝を露出させた。様々なサイズのタンタルマイクロクリップを使用して、動脈及び側枝を閉塞した。タンタルマイクロクリップは、血管造影検査時の良好なマーカーである。電気焼灼を使用して、腸骨動脈及び静脈並びに大腿動脈及び静脈を切除した。処置群の細胞懸濁液0.4ml又は対照群の0.9%生理食塩水を動物の腓腹筋に注射した。皮膚を断続縫合で閉じ、皮膚ステープラで固定した。アチパメゾール(5mg/ml、Syva社、スペイン)1mg/kgの皮下注射によって麻酔を回復させた。動物の体重を毎日測定し、疼痛の徴候についてモニターし、回復期間中に鎮痛薬(ブプレノルフィン(0.3mg/ml、Richterpharma社、オーストリア)0.01~0.03mg/kgを必要に応じて6~12時間毎に最低でも最初の3日間与え、ケトプロフェン(10mg/ml、Merial社、フランス)5mg/kgを必要に応じて24時間毎に最低5日間与えた。体重減少が20%を超えるか、又は重篤な疼痛及び苦痛若しくは瀕死の状態の累積的徴候が観察された場合、安楽死を適用した。
動物は全身麻酔下にあった(外科的介入の日には深部外科手術を行い、灌流測定のみには半量)。測定領域では、電気シェーバー及び除毛クリームを使用して毛を除去した。動物を、37℃の温度に維持するために、加熱され温度制御された表面に5分間置いた。測定にはPeriCam PSI(Perimed AB)を使用した。測定距離は15cmであった。加熱及び温度制御された表面で測定を行った。両肢において、関心領域(ROI)を選択した。測定は、手術前、手術直後、並びに手術の3、7及び14日後に行った。標準的な条件にもかかわらず、異なる動物は灌流が異なるので、同じ動物の手術肢と対照肢との差及び比較差を分析に使用した。
手術後14日目に血管造影を行った。動物は、加熱及び温度制御された表面上で、背臥位で全身麻酔をかけた。腹部大動脈を露出させた腹壁に正中切開を行った。大動脈カニューレ挿入のために、造影剤Omnipaque 300と共にMicroSlideキット(Galt Medical社)を使用した。デジタルサブトラクション血管造影を、Ziehm Vision RFD、20kW(Ziehm Imaging社)を使用して行った。
Microsoft Excel及びJMP10.0 SAS 統計解析ソフトウェアによって統計解析を行った。線形回帰を使用して、血管形成又は動脈形成と灌流との間の関係を分析した。カプラン・マイヤー法を使用して生存を分析し、一元配置分散分析(ANOVA)を使用して、異なる処置群間の灌流の平均差及び新しい血管の平均値を比較した。平均比較のために、ダネットの事後検定を使用して、処置群を生理食塩水対照群と比較した。手術前後で灌流差に変化がなかった場合(3灌流単位未満)、虚血のモデル化は動物において失敗したと考えられ、これらの全ての症例(3匹の生理食塩水処置対照動物)を統計分析から除外した。2つのシリーズのCYTORI処置動物が存在し、それらのうちの一方において、より高齢のラットが使用されたが、より高齢のCYTORI処置ラットとより若齢のCYTORI処置ラットとの間でいかなる測定値においても統計学的に有意な差がなかったので、これらの2つのシリーズの8匹の動物を1つの処置群(n=16)と見なした。
レーザードップラー血液灌流測定と血管造影所見との間の相関分析を図7に示す。
Claims (5)
- ヒトの肢虚血の治療における使用のための、メタミゾール処置された間葉系幹細胞を含む生成物。
- 患者の体重1kg当たり100万個のメタミゾール処置された間葉系幹細胞の用量で注射される、請求項1に記載の生成物。
- メタミゾール処置された間葉系幹細胞が、患者の体重1kg当たり75万~150万個の量で投与される、請求項1又は2に記載の生成物。
- 採取された脂肪組織から間葉系幹細胞(MSC)を分離することと、
MSCを再生することと、
MSCにメタミゾールを作用させることと、
を含む、請求項1に記載の生成物を生成する方法。 - インビトロで間葉系幹細胞(MSC)を活性化する方法であって、インビトロでMSCにメタミゾールを作用させることによって、前記MSCによる血管新生増殖因子VEGFA、HGF、bFGF、及びTEKの分泌を刺激し、前記MSCの炎症促進性サイトカインCCL2、及びIL1-RNのレベルを低下させることを含む、上記方法。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2019/057182 WO2021038275A1 (en) | 2019-08-27 | 2019-08-27 | Activated mesenchymal stem cells for treating limb ischemia |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022548500A JP2022548500A (ja) | 2022-11-21 |
JP7442624B2 true JP7442624B2 (ja) | 2024-03-04 |
Family
ID=68318916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022512807A Active JP7442624B2 (ja) | 2019-08-27 | 2019-08-27 | 肢虚血を治療するための活性化間葉系幹細胞 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220347223A1 (ja) |
EP (1) | EP4022039B1 (ja) |
JP (1) | JP7442624B2 (ja) |
KR (1) | KR20220047874A (ja) |
CN (1) | CN114269901A (ja) |
AU (1) | AU2019463156A1 (ja) |
CA (1) | CA3152963A1 (ja) |
HR (1) | HRP20240538T1 (ja) |
WO (1) | WO2021038275A1 (ja) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018236131A1 (ko) | 2017-06-20 | 2018-12-27 | 주식회사 툴젠 | 안지오포이에틴-1 또는 vegf를 분비하는 줄기세포 및 이를 포함하는 심혈관 질환의 예방 또는 치료용 약학 조성물 |
WO2019146131A1 (ja) | 2018-01-24 | 2019-08-01 | 学校法人順天堂大学 | 間葉系幹細胞による処置の効果を増幅するための組成物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201039815A (en) * | 2009-04-13 | 2010-11-16 | Resolvyx Pharmaceuticals Inc | Compositions and methods for the treatment of inflammation |
EP3366306B1 (en) * | 2016-12-23 | 2021-09-29 | Istanbul Üniversitesi Rektörlügü | Use of some peptides in diagnosis and treatment of diabetes, obesity and metabolic diseases associated thereto |
-
2019
- 2019-08-27 WO PCT/IB2019/057182 patent/WO2021038275A1/en unknown
- 2019-08-27 KR KR1020227009786A patent/KR20220047874A/ko unknown
- 2019-08-27 CA CA3152963A patent/CA3152963A1/en active Pending
- 2019-08-27 AU AU2019463156A patent/AU2019463156A1/en active Pending
- 2019-08-27 HR HRP20240538TT patent/HRP20240538T1/hr unknown
- 2019-08-27 JP JP2022512807A patent/JP7442624B2/ja active Active
- 2019-08-27 EP EP19791361.9A patent/EP4022039B1/en active Active
- 2019-08-27 CN CN201980099584.3A patent/CN114269901A/zh active Pending
- 2019-08-27 US US17/636,228 patent/US20220347223A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018236131A1 (ko) | 2017-06-20 | 2018-12-27 | 주식회사 툴젠 | 안지오포이에틴-1 또는 vegf를 분비하는 줄기세포 및 이를 포함하는 심혈관 질환의 예방 또는 치료용 약학 조성물 |
WO2019146131A1 (ja) | 2018-01-24 | 2019-08-01 | 学校法人順天堂大学 | 間葉系幹細胞による処置の効果を増幅するための組成物 |
Non-Patent Citations (1)
Title |
---|
Nicpon, J. et al.,The effect of metamizole and tolfenamic acid on canine and equine adipose-derived mesenchymal stem cells (ASCs) an in vitro research,Polish Journal of Veterinary Sciences,2015年,Vol. 18, No. 1,p. 3-11,doi:10.1515/pjvs-2015-0001 |
Also Published As
Publication number | Publication date |
---|---|
US20220347223A1 (en) | 2022-11-03 |
WO2021038275A1 (en) | 2021-03-04 |
KR20220047874A (ko) | 2022-04-19 |
EP4022039B1 (en) | 2024-04-03 |
EP4022039C0 (en) | 2024-04-03 |
CA3152963A1 (en) | 2021-03-04 |
CN114269901A (zh) | 2022-04-01 |
JP2022548500A (ja) | 2022-11-21 |
HRP20240538T1 (hr) | 2024-07-05 |
AU2019463156A1 (en) | 2022-03-03 |
EP4022039A1 (en) | 2022-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109414459A (zh) | 源自脐带血的外泌体用于组织修复的用途 | |
Sylakowski et al. | Mesenchymal stem cell/multipotent stromal cell augmentation of wound healing: lessons from the physiology of matrix and hypoxia support | |
CN109641013A (zh) | 包含凝血酶处理干细胞来源的外泌体的皮肤创伤的治疗用组合物 | |
Ham et al. | Subcutaneous priming of protein-functionalized chitosan scaffolds improves function following spinal cord injury | |
WO2013142192A1 (en) | Methods and compositions for regenerating and repairing damaged tissue using nonviable irradiated or lyophilized pluripotent stem cells | |
CN106074468B (zh) | 肉桂醛在制备能够诱导vegf表达和分泌的诱导剂中的用途 | |
JP2008534529A (ja) | 自家造血幹細胞の調製物、その製造方法、低温保存方法、および中枢神経系の外傷性疾患の治療のための使用 | |
CN109803664A (zh) | 用于改善细胞、组织和器官的活力和功能的试剂、组合物和方法 | |
Cheng et al. | Influence of human platelet lysate on extracellular matrix deposition and cellular characteristics in adipose-derived stem cell sheets | |
KR20210021165A (ko) | 지방줄기세포 유래 스페로이드를 포함하는 조건 배지를 유효성분으로 포함하는 상처 치유용 약학 조성물 | |
WO2015145370A1 (en) | Management of ischemia using pooled mesenchymal stromal cell composition | |
Kwon et al. | Synergic regenerative effects of polydeoxyribonucleotide and microcurrent on full-thickness rotator cuff healing in a rabbit model | |
KR101816964B1 (ko) | 피부 또는 혈관조직 손상 치료 보조용 약학 조성물 | |
JP7442624B2 (ja) | 肢虚血を治療するための活性化間葉系幹細胞 | |
RU2292212C1 (ru) | Кондиционная среда, обладающая лечебным эффектом | |
Cho et al. | Effect of human thymus adipose tissue-derived mesenchymal stem cells on myocardial infarction in rat model | |
CN114469981A (zh) | 尿苷在促进组织器官再生或治疗和/或预防和/或缓解和/或改善组织器官损伤中的应用 | |
US20180280434A1 (en) | Sequential application of macrophages for wound healing | |
Trofimova | Molecular Mechanisms of Retina Pathology and Ways of Its Correction | |
RU2301667C1 (ru) | Способ лечения заболеваний различной этиологии и травм различных органов | |
Gupta et al. | Future directions in the treatment of vitiligo | |
KR102017386B1 (ko) | 이식된 지방세포의 생착 증진용 조성물 및 지방 이식용 세포 치료제 조성물 | |
CN114560817B (zh) | 一种用于抑制纤维化的小分子药物及其应用 | |
KR20160144780A (ko) | 편도 유래 중간엽 줄기세포로부터 건 세포의 분화방법 | |
RU2299073C1 (ru) | Биотрансплантат и способ лечения хронической сердечной недостаточности (варианты) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A525 Effective date: 20220421 |
|
A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20220421 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220719 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220719 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230308 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230509 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230808 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240115 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240131 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240220 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7442624 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |